Literature DB >> 35640006

Which vaccination strategy against COVID-19?

Alessandro De Matteis1,2, Fethiye B Turkmen Ceylan1, Enrico Urpis3.   

Abstract

BACKGROUND: Bottlenecks in the production and supply pipeline of vaccines against coronavirus disease 2019 have led some countries to consider the option of dose-sparing strategies (e.g., increasing the number of people who receive some vaccine by halving the dose or increasing the interval between doses). In this study we assess the contribution of vaccination strategies to reducing the mortality induced by severe acute respiratory syndrome coronavirus 2.
METHODS: This study focuses on the evolution of the pandemic and related vaccination efforts in five countries that have adopted different vaccination strategies or have experienced a bottleneck in their vaccine supply. The analysis is conducted using an autoregressive time-series approach through a system of simultaneous equations.
RESULTS: The outcome of the early months of the vaccination campaign in containing the number of deaths induced by the epidemic varies across our sample. Overall, our results highlight the effective role played by the vaccine in containing the death toll induced by the epidemic. We could not find evidence of reduced effectiveness of the second dose in the presence of an extended inter-dose interval. The effectiveness of the vaccination campaign results appears to be strongly affected by the stability of vaccine supply.
CONCLUSIONS: The vaccine is effective in containing the deaths caused by the virus, particularly when multiple doses have been administered. The stability of the vaccine pipeline plays a critical role in determining the effectiveness of the vaccination campaign.
© The Author(s) 2022. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.

Entities:  

Keywords:  COVID-19; dose sparing; vaccination

Year:  2022        PMID: 35640006      PMCID: PMC9213840          DOI: 10.1093/inthealth/ihac023

Source DB:  PubMed          Journal:  Int Health        ISSN: 1876-3405            Impact factor:   3.131


  25 in total

1.  A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker).

Authors:  Thomas Hale; Noam Angrist; Rafael Goldszmidt; Beatriz Kira; Anna Petherick; Toby Phillips; Samuel Webster; Emily Cameron-Blake; Laura Hallas; Saptarshi Majumdar; Helen Tatlow
Journal:  Nat Hum Behav       Date:  2021-03-08

2.  Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.

Authors:  Laith J Abu-Raddad; Hiam Chemaitelly; Adeel A Butt
Journal:  N Engl J Med       Date:  2021-05-05       Impact factor: 91.245

3.  Modelling optimal vaccination strategy for SARS-CoV-2 in the UK.

Authors:  Sam Moore; Edward M Hill; Louise Dyson; Michael J Tildesley; Matt J Keeling
Journal:  PLoS Comput Biol       Date:  2021-05-06       Impact factor: 4.475

4.  Speed Versus Efficacy: Quantifying Potential Tradeoffs in COVID-19 Vaccine Deployment.

Authors:  A David Paltiel; Amy Zheng; Jason L Schwartz
Journal:  Ann Intern Med       Date:  2021-01-05       Impact factor: 25.391

5.  Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February.

Authors:  Daniel J Grint; Kevin Wing; Elizabeth Williamson; Helen I McDonald; Krishnan Bhaskaran; David Evans; Stephen Jw Evans; Alex J Walker; George Hickman; Emily Nightingale; Anna Schultze; Christopher T Rentsch; Chris Bates; Jonathan Cockburn; Helen J Curtis; Caroline E Morton; Sebastian Bacon; Simon Davy; Angel Ys Wong; Amir Mehrkar; Laurie Tomlinson; Ian J Douglas; Rohini Mathur; Paula Blomquist; Brian MacKenna; Peter Ingelsby; Richard Croker; John Parry; Frank Hester; Sam Harper; Nicholas J DeVito; Will Hulme; John Tazare; Ben Goldacre; Liam Smeeth; Rosalind M Eggo
Journal:  Euro Surveill       Date:  2021-03

Review 6.  Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination.

Authors:  Sarah Cobey; Daniel B Larremore; Yonatan H Grad; Marc Lipsitch
Journal:  Nat Rev Immunol       Date:  2021-04-01       Impact factor: 108.555

7.  BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.

Authors:  Noa Dagan; Noam Barda; Eldad Kepten; Oren Miron; Shay Perchik; Mark A Katz; Miguel A Hernán; Marc Lipsitch; Ben Reis; Ran D Balicer
Journal:  N Engl J Med       Date:  2021-02-24       Impact factor: 91.245

8.  Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study.

Authors:  Robert Challen; Ellen Brooks-Pollock; Jonathan M Read; Louise Dyson; Krasimira Tsaneva-Atanasova; Leon Danon
Journal:  BMJ       Date:  2021-03-09

9.  A Novel Vaccine Selection Decision-Making Model (VSDMM) for COVID-19.

Authors:  Sayed F Abdelwahab; Usama H Issa; Hossam M Ashour
Journal:  Vaccines (Basel)       Date:  2021-07-01

10.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.

Authors:  Jamie Lopez Bernal; Nick Andrews; Charlotte Gower; Eileen Gallagher; Ruth Simmons; Simon Thelwall; Julia Stowe; Elise Tessier; Natalie Groves; Gavin Dabrera; Richard Myers; Colin N J Campbell; Gayatri Amirthalingam; Matt Edmunds; Maria Zambon; Kevin E Brown; Susan Hopkins; Meera Chand; Mary Ramsay
Journal:  N Engl J Med       Date:  2021-07-21       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.